Overview

Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage

Status:
Completed
Trial end date:
2017-05-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and potential therapeutic benefit of use of clazosentan in reversing cerebral vasospasm (a narrowing of blood vessels in the brain due to the presence of blood in the space around the brain) in patients who have suffered a condition known as aneurysmal subarachnoid hemorrhage caused by bleeding onto the surface of the brain from a ruptured brain aneurysm
Phase:
Phase 2
Details
Lead Sponsor:
Actelion
Idorsia Pharmaceuticals Ltd.